iBio, Inc. Form 10-Q Summary
Business context and reporting period
iBio, Inc. is a biotechnology company and biologics contract development and manufacturing organization (CDMO) using its FastPharming platform. Its activities include CDMO services, therapeutics, vaccines, and research and bioprocess products. The filing covers the quarter and six months ended December 31, 2020, the Company’s fiscal second quarter, with comparisons to the same periods in 2019.
During the second half of 2020, the Company shifted its primary focus toward biologics development programs, including vaccine and therapeutic candidates. Beginning with the quarter ending March 31, 2021, management expected to report separate therapeutics, vaccines, and research and bioprocess product profit centers.
Financial performance and liquidity
| Metric | Three months ended December 31 | Six months ended December 31 |
|---|---|---|
| Revenue | $705,000, versus $314,000 | $1.115 million, versus $422,000 |
| Operating expenses | $8.250 million, versus $3.469 million | $15.584 million, versus $7.432 million |
| Operating loss | $7.545 million, versus $3.155 million | $14.469 million, versus $7.010 million |
| Net loss attributable to iBio | $8.129 million, versus $3.762 million | $15.662 million, versus $8.225 million |
| Net loss available to common stockholders | $8.194 million, or $0.04 per share | $15.793 million, or $0.09 per share |
| Operating cash flow | Not separately provided | $(15.489) million |
- Quarterly revenue increased approximately 124%, while six-month revenue increased approximately 164% year over year. Revenue was generated from four customers in both periods; one customer represented 63.8% of quarterly revenue.
- Quarterly R&D expense increased to $2.444 million from $888,000, primarily due to laboratory supplies and personnel. Six-month R&D expense increased to $4.206 million from $1.865 million.
- Quarterly G&A expense increased to $5.806 million from $2.581 million, driven by professional and consulting fees, facility repairs, personnel, public-company costs, insurance, and board fees.
- The Company remained deeply unprofitable. Quarterly operating margin was approximately negative 1,070%, and net margin was approximately negative 1,155%; these ratios reflect the small revenue base and should not be interpreted as normalized margins.
- Cash and cash equivalents were $91.252 million at December 31, 2020, compared with $55.112 million at June 30, 2020. Investments in debt securities were $16.395 million, bringing cash and debt securities to approximately $107.6 million.
- Financing activities provided $71.185 million during the six months, primarily from equity issuances. Investing activities used $19.556 million, including purchases of debt securities and a $1.5 million convertible note receivable from Safi.
- Total liabilities were $38.085 million. The Company had a $600,000 PPP loan and finance lease obligations totaling approximately $32.160 million, including a $31.848 million non-current portion. The 34-year facility sublease carries scheduled minimum payments of approximately $80.4 million, including interest, through its remaining term.
- Stockholders’ equity increased to $107.321 million from $56.607 million at June 30, 2020, largely because of equity issuances. Common shares outstanding increased to 211.8 million from 140.1 million.
Material changes versus the prior comparable period
- Revenue improved substantially, but operating expenses grew faster than revenue, resulting in a larger operating loss of $7.545 million versus $3.155 million for the quarter.
- The prior-year quarterly and six-month common-stockholder losses included a $21.560 million deemed dividend related to down-round features of Series A and Series B preferred stock. That nonrecurring item was absent in 2020, making reported per-share losses appear materially improved despite higher operating losses.
- All Series B Preferred Stock was converted into 28.925 million common shares in August 2020. The Company also issued approximately 30.2 million shares under its UBS equity distribution agreement and approximately 29.7 million shares in a December 2020 underwritten offering.
- Capital raises materially strengthened liquidity but substantially increased the share count and potential dilution. The Company terminated the UBS agreement on November 25, 2020 and established a new Cantor Fitzgerald at-the-market facility with capacity of up to $100 million; no sales had been made under that facility as of the filing date.
- Management stated that the Company had regained compliance with all NYSE American continued-listing standards by October 1, 2020.
Guidance, outlook, risks, contingencies, and unusual items
- Management believes existing cash and liquid investments, including approximately $4.7 million of net proceeds from a January 2021 partial exercise of the Cantor Fitzgerald option, are sufficient to fund operations through March 31, 2023. This is management’s estimate and is dependent on expected spending and operating conditions.
- The Company expects continued losses and negative operating cash flow and may require additional financing. Future equity financing could dilute stockholders; unavailable or unfavorable financing could require delays, reductions, or discontinuation of development programs.
- COVID-19 reduced CDMO capacity at times and caused a three-day facility shutdown in April 2020. Management did not anticipate a significant immediate operational threat but could not estimate future effects on operations or liquidity.
- The Company recorded a $497,000 reserve for an anticipated contract loss during the quarter.
- The Company licensed Planet Biotechnology’s ACE2-F COVID-19 therapeutic candidate for an upfront payment of $150,000 and potential milestone payments totaling up to $7.15 million, payable in cash or, at the Company’s option, equivalent stock.
- IBIO-201 was selected as the lead COVID-19 vaccine candidate after preclinical studies. The candidate remained in preclinical development and required further toxicology, clinical testing, and regulatory approval.
- The Company’s University of Pittsburgh license for IBIO-100 requires an Investigational New Drug application filing by December 31, 2021, along with additional development milestones. Failure to meet obligations could jeopardize the license.
- The Company is involved in ongoing litigation with Fraunhofer concerning technology ownership, contract, trade secret, and related claims. Trial was scheduled for March 1–5, 2021, and the Company stated that it could not predict the outcome.
- The PPP loan remained outstanding at $600,000. Forgiveness had not been requested as of the filing date, and forgiveness was not assured.
- Management planned to liquidate inactive iBio Brazil in the third quarter of fiscal 2021, with no material consolidated impact expected.
- The Company reported effective disclosure controls as of December 31, 2020 and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the Company’s cash runway through March 31, 2023 remains achievable given continued losses, approximately $15.5 million of six-month operating cash use, and planned development spending.
- Progress, costs, regulatory milestones, and clinical-readiness of IBIO-100, IBIO-201, IBIO-200, and the licensed ACE2-F program.
- Customer concentration, CDMO facility utilization, contract backlog, and the financial effect of the $497,000 anticipated contract loss.
- Potential dilution from the 275 million authorized common shares, the Cantor Fitzgerald $100 million facility, equity incentive plans, and other reserved or issuable shares.
- Outcome and potential financial or intellectual-property consequences of the Fraunhofer litigation and compliance with the University of Pittsburgh license milestones.
- Status of PPP loan forgiveness and the Company’s long-term finance lease obligations and related-party arrangements.